Skip to content
10-Q

Quarterly Report

TEVA PHARMACEUTICAL INDUSTRIES LIMITED TEVA TEVJF

0001193125-26-191513

← back to feed
Filed
Apr 29, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted Q1 2026 · Mar 31, 2026 1.18B sh
Shares Diluted Q1 2026 · Mar 31, 2025 1.16B sh
Shares Outstanding Q1 2026 · Mar 31, 2026 1.16B sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$40M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$105M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $3.74B
Cash And Equivalents Q1 2026 · Dec 31, 2025 $3.56B
Stockholders Equity Q1 2026 · Mar 31, 2026 $8.23B
Stockholders Equity Q1 2026 · Dec 31, 2025 $7.91B
Current Liabilities Q1 2026 · Mar 31, 2026 $13.53B
Current Liabilities Q1 2026 · Dec 31, 2025 $13.46B
Total Liabilities Q1 2026 · Mar 31, 2026 $31.81B
Total Liabilities Q1 2026 · Dec 31, 2025 $32.83B
Current Assets Q1 2026 · Mar 31, 2026 $13.71B
Current Assets Q1 2026 · Dec 31, 2025 $13.95B
Total Assets Q1 2026 · Mar 31, 2026 $40.04B
Total Assets Q1 2026 · Dec 31, 2025 $40.75B
Eps Diluted Q1 2026 · Mar 31, 2026 $0.31
Eps Diluted Q1 2026 · Mar 31, 2025 $0.18
Eps Basic Q1 2026 · Mar 31, 2026 $0.32
Eps Basic Q1 2026 · Mar 31, 2025 $0.19
Sga Expense Q1 2026 · Mar 31, 2026 $304M
Sga Expense Q1 2026 · Mar 31, 2025 $297M
Net Income Q1 2026 · Mar 31, 2026 $369M
Net Income Q1 2026 · Mar 31, 2025 $214M
Operating Income Q1 2026 · Mar 31, 2026 $652M
Operating Income Q1 2026 · Mar 31, 2025 $519M
Gross Profit Q1 2026 · Mar 31, 2026 $1.97B
Gross Profit Q1 2026 · Mar 31, 2025 $1.88B
Cost Of Revenue Q1 2026 · Mar 31, 2026 $2.01B
Cost Of Revenue Q1 2026 · Mar 31, 2025 $2.01B
Revenue Q1 2026 · Mar 31, 2026 $3.98B
Revenue Q1 2026 · Mar 31, 2025 $3.89B